EndometritisPhase 2NCT02742948
The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section
A Phase 2 study testing ceftriaxone in people with Endometritis, run by Cairo University.
Trial summary
Objective: To determine the optimal time for intravenous antibiotic prophylaxis administration in pregnant women undergoing elective cesarean section to minimize postpartum infectious complication for both the mother \& neonate. Study Design: A randomized comparative study. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Endometritis
- What is being tested?
- ceftriaxone
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 600 participants
- Where
- No sites listed yet
- Study dates
- Apr 2016to Sep 2016
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- pregnant women in singleton living healthy fetuses. gestational age (GA) more than 37 weeks gestation
Who cannot join
- Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes). Previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin
Trial locations and contacts
No sites are listed yet.
About this study
Official title: The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section: Randomized Comparative Study
Objective: To determine the optimal time for intravenous antibiotic prophylaxis administration in pregnant women undergoing elective cesarean section to minimize postpartum infectious complication for both the mother \& neonate.
Study Design: A randomized comparative study. Setting: The Obstetrics and Gynecology department of Kasr El Aini hospital (Cairo University - Egypt) in the period from April 2016 to September 2016.
Methodology: Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS).They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Outcomes include postoperative maternal \& fetal infectious morbidity.
Read the detailed description
Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS); defined as LSCS done before onset of labor pains, will be enrolled in the study. They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Randomization will be done using computer generated random numbers.
Another inclusion criterion includes gestational age (GA) more than 37 weeks gestation. Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes) will be excluded from the study. Additional exclusion criteria include previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin will be also excluded (all patients will receive 100 mg of ceftriaxone as a test dose before participation in the current study). The study was approved by the Hospital Ethical Committee. All participants will provide an informed consent after explaining the aim and potential hazards of the study.
For all patients, full history will be taken followed by complete physical examination, obstetric ultrasound \& routine preoperative investigations. GA is established by menstrual dates then confirmed by obstetric ultrasound. Spinal anaesthesia will be given for all patients. All cesarean sections will be done by ob/gyn residents under the supervision of senior staff obstetrician using the following technique: Pfannenstiel skin incision, transverse lower uterine segment incision, two-layer closure of the uterine wall, closure of both parietal peritoneum \& rectus sheath \& skin closure (using prolene 3/0 suture). Primary maternal outcome includes postoperative endometritis (diagnosed if maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis).Secondary maternal outcomes include wound infection (diagnosed if there is induration, redness, hematoma, seroma or purulent discharge at the incision site) \& urinary tract infection (diagnosed if there frequency, dysuria, suprapubic or loin pain \& positive urine culture). Prolonged postoperative hospital stay (more than 2 days) will also be recorded. The infectious morbidity evaluation will be done by ob/gyn residents who will be blinded to the study group of the patient. Neonatal outcomes include immediate antibiotic adverse effects (diarrhea \& rash), neonatal sepsis (diagnosed by clinical signs, leukocytosis, C-reactive protein\& positive blood culture), neonatal intensive care unit (NICU) admission (entailing the length of stay) \& neonatal death. All neonates will be examined by an expert neonatologist who will be blinded to study group of the neonate's mother. On discharging all patients, a brief summary about symptoms and signs of the above mentioned infectious \& neonatal complications will be given and they will be instructed to contact any of the authors immediately if any happens. Patients will be reexamined after 1 week (skin stitch removal appointment) \& 4 weeks (contraception counseling appointment) following the CS.
- Conditions
- Endometritis
- Being tested
- ceftriaxone
- Keywords
- elective caesarean section, antibiotics, endometritis
- Medical subject headings
- Endometritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ceftriaxoneDrug
Also called Rocephin
IV ceftriaxone (2g) will be given to all participants
| Study group | Role | What they receive |
|---|---|---|
| preoperative antibiotic group | Active comparator | 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision Receives: Drug: ceftriaxone |
| early intraoperative antibiotic group | Active comparator | 200 women will receive IV ceftriaxone (2g) immediately with skin incision Receives: Drug: ceftriaxone |
| post cord clamping antibiotic group | Active comparator | 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping Receives: Drug: ceftriaxone |
What is being measured
The primary outcome is the main question the study is designed to answer.
endometritis
maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis.
Measured: up to 4 weeks postoperative
Secondary outcomes (6)
neonatal immediate side effects
diarrhea \& fever
Measured: within 24 hours postoperative
neonatal sepsis
clinical signs, leukocytosis, CRP \& positive blood culture
Measured: up to 1 week postoperative
neonatal ICU admission
Measured: within 24 hours postoperative
Prolonged hospital stay
Measured: 2 days
wound infection
induration, redness, hematoma, seroma or purulent discharge at the incision site
Measured: up to 4 weeks postoperative
urinary tract infection
frequency, dysuria, suprapubic or loin pain \& positive urine culture.
Measured: up to 4 weeks postoperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2016 (estimated)
- Study startApr 2016
- Primary completionAug 2016 (estimated)
- Study completionSep 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometritisStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Moutaz Sherbini, Cairo University
- Investigators
- Moutaz Elsherbini, MD, Principal investigator, Lecturer of obstetrics & gynaecology - Cairo university
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02742948
- Sponsor's protocol ID
- 821978
- Status last verified
- Apr 2016
- First submitted
- 30 Mar 2016
- Last updated
- 19 Apr 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Apr 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section: Randomized Comparative Study
- ClinicalTrials.gov ID
- NCT02742948
- Acronym / sponsor ID
- 821978
- Conditions
- Endometritis
- Keywords
- elective caesarean section, antibiotics, endometritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- Apr 2016
- Primary completion
- Aug 2016 (estimated)
- Study completion
- Sep 2016 (estimated)
- First posted
- 19 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: To determine the optimal time for intravenous antibiotic prophylaxis administration in pregnant women undergoing elective cesarean section to minimize postpartum infectious complication for both the mother \& neonate.
Study Design: A randomized comparative study. Setting: The Obstetrics and Gynecology department of Kasr El Aini hospital (Cairo University - Egypt) in the period from April 2016 to September 2016.
Methodology: Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS).They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Outcomes include postoperative maternal \& fetal infectious morbidity.
Detailed description
Six hundred pregnant women aged from 20 to 40 years old with singleton living healthy fetuses undergoing elective lower segment caesarean section (LSCS); defined as LSCS done before onset of labor pains, will be enrolled in the study. They will be randomized into three groups: group A in which 200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision, group B in which 200 women will receive IV ceftriaxone (2g) immediately with skin incision \& group C in which 200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping. Randomization will be done using computer generated random numbers.
Another inclusion criterion includes gestational age (GA) more than 37 weeks gestation. Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes) will be excluded from the study. Additional exclusion criteria include previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin will be also excluded (all patients will receive 100 mg of ceftriaxone as a test dose before participation in the current study). The study was approved by the Hospital Ethical Committee. All participants will provide an informed consent after explaining the aim and potential hazards of the study.
For all patients, full history will be taken followed by complete physical examination, obstetric ultrasound \& routine preoperative investigations. GA is established by menstrual dates then confirmed by obstetric ultrasound. Spinal anaesthesia will be given for all patients. All cesarean sections will be done by ob/gyn residents under the supervision of senior staff obstetrician using the following technique: Pfannenstiel skin incision, transverse lower uterine segment incision, two-layer closure of the uterine wall, closure of both parietal peritoneum \& rectus sheath \& skin closure (using prolene 3/0 suture). Primary maternal outcome includes postoperative endometritis (diagnosed if maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis).Secondary maternal outcomes include wound infection (diagnosed if there is induration, redness, hematoma, seroma or purulent discharge at the incision site) \& urinary tract infection (diagnosed if there frequency, dysuria, suprapubic or loin pain \& positive urine culture). Prolonged postoperative hospital stay (more than 2 days) will also be recorded. The infectious morbidity evaluation will be done by ob/gyn residents who will be blinded to the study group of the patient. Neonatal outcomes include immediate antibiotic adverse effects (diarrhea \& rash), neonatal sepsis (diagnosed by clinical signs, leukocytosis, C-reactive protein\& positive blood culture), neonatal intensive care unit (NICU) admission (entailing the length of stay) \& neonatal death. All neonates will be examined by an expert neonatologist who will be blinded to study group of the neonate's mother. On discharging all patients, a brief summary about symptoms and signs of the above mentioned infectious \& neonatal complications will be given and they will be instructed to contact any of the authors immediately if any happens. Patients will be reexamined after 1 week (skin stitch removal appointment) \& 4 weeks (contraception counseling appointment) following the CS.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| preoperative antibiotic group | Active comparator | Drug: ceftriaxone200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision |
| early intraoperative antibiotic group | Active comparator | Drug: ceftriaxone200 women will receive IV ceftriaxone (2g) immediately with skin incision |
| post cord clamping antibiotic group | Active comparator | Drug: ceftriaxone200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- pregnant women in singleton living healthy fetuses. gestational age (GA) more than 37 weeks gestation
Key exclusion criteria (1 listed)
- Patients on immunosuppressant drugs, received any antibiotic prophylaxis (within 10 days), suffer any chronic illness (e.g. diabetes mellitus or renal disease) or who experienced any obstetric complication in the current pregnancy (e.g. antepartum hemorrhage \& rupture of membranes). Previous history of more than two laparotomies, maternal BMI more than 28 \& any maternal febrile illness within 10 days from the procedure. Patients who are known to be allergic to penicillin or cephalosporin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ceftriaxoneAlso: RocephinIV ceftriaxone (2g) will be given to all participants | Drug | early intraoperative antibiotic group, post cord clamping antibiotic group, preoperative antibiotic group |
Primary outcome
endometritis
Time frame: up to 4 weeks postoperative
maternal axillary temperature ≥ 38°C for at least 48 hours, uterine tenderness, infected lochia \& leukocytosis.
6 secondary outcomes
neonatal immediate side effects
Time frame: within 24 hours postoperative
neonatal sepsis
Time frame: up to 1 week postoperative
neonatal ICU admission
Time frame: within 24 hours postoperative
Prolonged hospital stay
Time frame: 2 days
wound infection
Time frame: up to 4 weeks postoperative
urinary tract infection
Time frame: up to 4 weeks postoperative
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Apr 2016.
Related trials for Endometritis
Not yet recruitingObservational study
Hysteroscopy and CD138+ Plasma Cell Density in Chronic Endometritis
Chronic Endometritis
Not yet recruiting
Effect of Betadine Vaginal Cleansing Before Cesarean Section to Reduce Postoperative Infectious Morbidity
Cesarean Section, Surgical Site Infection
Not yet recruitingPhase 4
Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy
Minimally Invasive Surgical Procedures, Abnormal Uterine Bleeding, Unspecified
Not yet recruitingObservational study
GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET
Chronic Endometritis
RecruitingObservational study
Fertility Outcomes After Antibiotic Treatment In Women With Chronic Endometritis
Endometritis, Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Moutaz Elsherbini, MD principal investigator
Lecturer of obstetrics & gynaecology - Cairo university
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing ceftriaxone in people with Endometritis, run by Cairo University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact MOUTAZ ELSHERBINI, MD ((+2) 01001588300, mizosherbini@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
endometritis (time frame: up to 4 weeks postoperative). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2016.